Breast cancer is the leading cause of cancer-related deaths for women worldwide

Despite advances in diagnostic tools and therapies available, approximately 1 in 6 patients diagnosed with HR+/HER2- early breast cancer will experience disease recurrence within 5 years of treatment.

This expert-led program aims to improve the individualized management of HR+/HER2- early breast cancer through education on recurrence risk classification, current evidence-based guidelines, and new and emerging therapies.

There will also be guidance on integrating shared decision making into your practice drawing on insights from a patient on how best to communicate.